Significant correlation between the degree of WT1 expression and the international prognostic scoring system score in patients with myelodysplastic syndromes

Journal of Clinical Oncology

Volumn 21, Issue 10, 2003, Pages 1988-1995

  Cilloni, Daniela ^a   Gottardi, Enrico ^a   Messa, Francesca ^a   Fava, Milena ^a   Scaravaglio, Patrizia ^a   Bertini, Marilena ^a   Girotto, Mauro ^a   Marinone, Carlo ^a   Ferrero, Dario ^a   Gallamini, Andrea ^a   Levis, Alessandro ^a   Saglio, Giuseppe ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN WT1; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; PRIMER DNA; TUMOR MARKER; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BLAST CELL; BONE MARROW CELL; CANCER RISK; CHROMOSOME 5Q; CHROMOSOME DELETION 5; CYTOGENETICS; DISEASE COURSE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REFRACTORY ANEMIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; TUMOR SUPPRESSOR GENE; BLOOD; BONE MARROW; CASE CONTROL STUDY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOPHENOTYPING; METABOLISM; MYELOID LEUKEMIA; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; REGRESSION ANALYSIS;

BONE MARROW; CASE-CONTROL STUDIES; DISEASE PROGRESSION; DNA PRIMERS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID; MYELODYSPLASTIC SYNDROMES; POLYMERASE CHAIN REACTION; PROGNOSIS; REGRESSION ANALYSIS; TUMOR MARKERS, BIOLOGICAL; WT1 PROTEINS;

EID: 0038011942     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.10.503     Document Type: Article

References (34)

1. Heaney ML, Golde DW: Myelodysplasia. N Engl J Med 340:1649-1660, 1999
2. Lowenthal RM, Marsden KA: Myelodysplastic syndromes. Int J Hematol 65:319-338, 1997
3. Hofmann WK, Ottmann OG, Ganser A, et al: Myelodysplastic syndromes: Clinical features. Semin Hematol 33:177-185, 1996
4. Foucar K, Langdon RM II, Armitage JO, et al: Myelodysplastic syndromes: A clinical and pathologic analysis of 109 cases. Cancer 56:553-561, 1985
5. Sanz GF, Sanz MA, Vallespi T: Etiopathogeny, prognosis and therapy of myelodysplastic syndromes. Hematol Cell Ther 39:277-294, 1997
6. Bennett JM, Catovsky D, Daniel MT, et al: Proposal for the classification of the myelodysplastic syndromes. Br J Haematol 51:189-199, 1982
7. Verhoef GE, Pittaluga S, De Wolf-Peeters C, et al: FAB classification of myelodysplastic syndromes: Merits and controversies. Ann Hematol 71:3-11, 1995
8. Bennett JM: World Health Organization classification of the acute Ieukemias and myelodysplastic syndrome. Int J Hematol 72:131-133, 2000
9. Mijovic A, Mufti GJ: The myelodysplastic syndromes: Towards a functional classification. Blood Rev 12:73-83, 1998
10. Greenberg P, Anderson J, de Witte T, et al: Problematic WHO reclassification of myelodysplastic syndromes: Members of the International MDS Study Group. J Clin Oncol 18:3447-3452, 2000
11. Greenberg P, Cox C, LeBeau MM, et al: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088, 1997
12. Sanz GF, Sanz MA, Greenberg PL: Prognostic factors and scoring systems in myelodysplastic syndromes. Haematologica 83:358-368, 1998
13. Heim S, Mitelman F: Chromosome abnormalities in the myelodysplastic syndromes. Clin Haematol 15:1003-1021, 1986
14. Yunis JJ, Lobell M, Arnesen MA, et al: Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukemia. Br J Haematol 68:189-194, 1988
15. Nowell PC: Chromosome abnormalities in myelodysplastic syndrome and acute myelogenous leukemia. Semin Oncol 19:25-33, 1992
16. Call KM, Glaser T, Ito CY, et al: Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 60:509-520, 1990
17. Haber DA, Buckler AJ: WT1: A novel tumor suppressor gene inactivated in Wilms' tumor. New Biol 4:97-106, 1992
18. Haber DA, Housman DE: Role of the WT1 gene in Wilms' tumor. Cancer Surv 12:105-117, 1992
19. Park S, Schalling M, Bernard A, et al: The Wilms tumor gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma. Nat Genet 4:415-420, 1993
20. Baird PN, Simmons PJ: Expression of the Wilms' tumor gene (WT1) in normal hematopoiesis. Exp Hematol 25:312-320, 1997
21. Cilloni D, Gottardi E, De Micheli D, et al: Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 16:2115-2121, 2002
22. Inoue K, Ogawa H, Sonoda Y, et al: Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 89:1405-1412, 1997
23. Inoue K, Sugiyama H, Ogawa H, et al: WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 84:3071-3079, 1994
24. Inoue K, Ogawa H, Yamagami T, et al: Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. Blood 88:2267-2278, 1996
25. Harnden DG, Klinger HP: An International System for Human Cytogenetic Nomenclature (1985): Report of the Standing Committee on Human Cytogenetic Nomenclature. Basel, Switzerland, Karger, 1985
26. Lacombe F, Durrieu F, Briais A, et al: Flow cytometry CD45 gating for immunophenotyping of acute myeloid leukemia. Leukemia 11:1878-1886, 1997
27. Van Dongen JJ, Macintyre EA, Gabert JA, et al: Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease: Report of the BIOMED-1 Concerted Action-Investigation of minimal residual disease in acute leukemia. Leukemia 13:1901-1928, 1999
28. Spinsanti P, de Grazia U, Faggioni A, et al: Wilms' tumor gene expression by normal and malignant human B lymphocytes. Leuk Lymphoma 38:611-619, 2000
29. Shichishima T, Okamoto M, Ikeda K, et al: HLA class II haplotype and quantitation of WT1 RNA in Japanese patients with paroxysmal nocturnal hemoglobinuria. Blood 100:22-28, 2002
30. Tamaki H, Ogawa H, Ohyashiki K, et al: The Wilms' tumor gene is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia 13:393-399, 1999
31. Patmasiriwat P, Fraizer G, Kantarjian H, et al: WT1 and GATA1 expression in myelodysplastic syndrome and acute leukemia. Leukemia 13:891-900, 1999
32. Elisseeva OA, Oka Y, Tsuboi A, et al: Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood 99:3272-3297, 2002
33. Pallisgaard N, Hokland P, Bi W, et al: Selection of reference gene for the European standardization and quality control program of real-time quantitative RT-PCR analysis of fusion gene transcripts for minimal residual disease follow-up in leukemia patients. Blood 98:192b, 2001 (abstr 4467)
34. Gao L, Bellantuono I, Elsasser A, et al: Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 95:2198-2203, 2000